MDCX Medicus Pharma Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1997296 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY160.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-415.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets172.2%
Debt / equity—
Current ratio0.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-101.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $7.72M | $3.53M | $193,578 |
| SG&A expense | $17.92M | $7.65M | $4.54M |
| Operating income | -$34.36M | -$11.18M | -$4.73M |
| Pretax income | -$16.82M | -$6.19M | -$3.29M |
| Income tax | $0 | $0 | $0 |
| Net income | -$47.28M | -$11.16M | -$5.31M |
| EPS (basic) | -2.74 | -1.16 | -1.53 |
| EPS (diluted) | -2.74 | -1.16 | -1.53 |
| Weighted avg. shares (diluted) | 17.28M | 9.62M | 3.48M |
| Banking | |||
| Net interest income | -$197,382 | $25,386 | — |
| Balance sheet | |||
| Cash & equivalents | $8.71M | $4.16M | $1.72M |
| Current assets | $9.89M | $5.38M | $1.89M |
| Total assets | $10.06M | $5.65M | $1.89M |
| Current liabilities | $9.94M | $2.31M | $781,609 |
| Short-term debt | $5.25M | $0 | — |
| Total liabilities | $10.02M | $2.51M | $781,609 |
| Shareholders' equity | -$67,554 | $3.13M | $1.11M |
| Shares outstanding | 503,526 | 11.82M | 8.08M |
| Cash flow statement | |||
| Operating cash flow | -$22.78M | -$10.25M | -$4.16M |
| Investing cash flow | -$4.62M | $0 | — |
| Financing cash flow | $31.94M | $12.69M | $5.61M |
| Stock-based compensation | $1.51M | $713,119 | $98,585 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.